biolitec AG: EBIT rises to 1.5 million Euro in Q3 2009/2010 - biolitec's medication Foscan(R) becomes hope for patients with head and neck cancer

biolitec AG / Quarter Results

31.05.2010 09:31

Dissemination of an Ad hoc announcement according to § 15 WpHG,
transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

biolitec AG: EBIT rises to 1.5 million Euro in Q3 2009/2010 - biolitec's
medication Foscan(R) becomes hope for patients with head and neck cancer



Jena/Germany, May 31, 2010 - biolitec AG, Jena, listed in the Prime
Standard of the Frankfurt stock exchange (ISIN DE0005213409), realized a
gross profit of 15 million Euro (previous year: 16.2 million Euro) in the
first three quarters of the fiscal year 2009/2010. The revenue reached 21.9
million Euro (previous year: 23.3 million Euro). The profit per share in
the first nine months of the fiscal year is 0.13 Euro compared to - 0.01
Euro one year ago. The EBIT in the first nine months amounts to 1.5 million
Euro compared to - 0.7 Euro in 2008/2009. With this, biolitec has already
exceeded the previous year's result in the reference period by over 2.2
million Euro.

The 9 month turnover 2009/2010 is almost at the level of the previous year.
Furthermore, biolitec clearly improved the profit situation due to the
initiated rationalization and diversification strategies and the
strengthening of the global presence.

The business segment pharmaceuticals has achieved considerable success in
the third quarter with the Dutch cost reimbursement of the head and neck
cancer drug Foscan(R). Concerning the cancer therapy with biolitec's
approved medication patients now can get free treatment with this new PDT
drug in the Netherlands. Due to an initiated cost benefit study of the
Dutch health authority with leading hospitals and academic centres in the
Netherlands, leading experts are confident, that the high-tech treatment
will emerge as an important and cost effective treatment option in Europe
and more patients will profit from the reimbursement in the future. As a
recently published study shows, 68% of the patients (characterized as
otherwise untreatable) respond to Foscan PDT treatment. The probability of
living another five years tumor-free is 27% for these patients, who were
otherwise unresponsive to further treatment - with photodynamic therapy and
the medication Foscan(R) healing now seems possible even in such cases.

biolitec's reimbursable methods of treatment such as the innovative vein
treatment ELVeS(R) PainLess or the BPH (benign prostate hyperplasia)
treatment LIFE(TM) are a sound basis for biolitec's long-term growth. Our
focus to generate per procedure revenue through disposable and pharma sales
has already become noticeable in the fiber optics segment with an increase
of turnover by 6% to 16.46 million Euro.

The major revenues came from Europe and North America. With 8.5 million
Euro, sales in North America were at the previous years level. Sales in
Europe decreased by 12% to 10.4 million Euro (previous year: 11.9 million).

The number of employees has stabilized at the level of 222. In the first
nine month of the fiscal year 2009/10, our expenditures in research and
development remained on a high level.

For the fourth quarter biolitec expects the business performance to remain
stable.


31.05.2010 Ad hoc announcement, Financial News and Media Release
distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0) 3641 508 550
Fax:          +49 (0) 3641 508 599
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Düsseldorf, Stuttgart, Hamburg
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------